Neutrophil to lymphocyte ratio in the pre-treatment phase of final-line chemotherapy predicts the outcome of patients with recurrent ovarian cancer

Keiichiro Nakamura, Takeshi Nagasaka, Takeshi Nishida, Tomoko Haruma, Chikako Ogawa, Tomoyuki Kusumoto, Noriko Seki, Yuji Hiramatsu

Research output: Contribution to journalArticle

23 Citations (Scopus)


Inflammation and tumor immunology are associ­ated with prognosis in a variety of cancers. The aim of the present retrospective study was to identify associations between the neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), cancer antigen 125 (CA125) concentrations, tumor response, performance status (PS) and survival of patients that developed recurrent ovarian cancer subsequent to receiving chemotherapy. The NLR and PLR measured prior to fourth-line chemotherapy were signifi­cantly increased compared with those measured prior to second-line chemotherapy (P=0.029 and 0.049, respectively). By using receiver operating characteristic curves, the cut-off values were determined for the NLR, PLR and CA125 levels that were measured during the pre-treatment phase, which predicted the outcomes. According to univariate analyses, pre-treatment NLR >3.91, PLR >299.0 and PS 2 were each significantly associated with poor outcomes (P=0.001, 0.005 and 0.021, respectively). According to multivariate analyses, only pre-treatment NLR was associated with poor outcome (P=0.035). The present findings indicate that pre-treatment NLR is an important predictor of prognosis in patients with ovarian cancer that experience recurrence following chemotherapy.

Original languageEnglish
Pages (from-to)3975-3981
Number of pages7
JournalOncology Letters
Issue number6
Publication statusPublished - Jun 1 2016



  • Chemotherapy
  • Neutrophil to lymphocyte ratio
  • Predictor of survival
  • Recurrent ovarian cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this